Effect of Tamsulosin vs Prazosin in Treatment of Female Voiding Dysfunction

Neurogenic Bladder Clinical Trial

Official title:

Effect of Tamsulosin vs Prazosin in Treatment of Female Voiding Dysfunction

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00602186
• Other study ID #: 85-1
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• First received: April 18, 2007
• Last updated: January 26, 2008
• Start date: July 2005
• Est. completion date: March 2008

Study information

• Verified date: January 2008
• Source: Tabriz University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether Tamsolusin or Prazosin are effective in the treatment of female voiding dysfunction(BOO)

Description:

Voiding dysfunction is not uncommon in Tabriz.About 20% of patients in female urology clinic of Tabriz university of medical sciences sufered from some degrees of voiding dysfunction (due to bladder imparement or bladder outlet obstruction).There is limited information about medical treatment of those patients. On the other hand alpha adrenergic blockers are the first choice medication in BENIGN PROSTATIC HYPERPLASIA. There is some new facts about destribution of alpha adrenergic blockers in female pelvic floor.The purpose of this study is to comparision whether Tamsolusin 0.4/daily or Prazosin 1 mg/daily are effective in the treatment of female voiding dysfunction(BOO)

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 80
• Est. completion date: March 2008
• Est. primary completion date: March 2007
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years to 70 Years

Eligibility

Inclusion Criteria:

• Healthy females with voiding difficulty with MFR<12 and post void residual urine>50cc

Exclusion Criteria:

• History of pelvic floor surgury during last 3 month

• Any contraindication for Tamsolusin or prazosin

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Neurogenic Bladder
• Urinary Bladder, Neurogenic

Intervention

Drug:
• tamsolusin
0.4 mg /day
• prazosin
1 mg/day

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Tabriz University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	patient symptoms improvement(Standard questionare)		every month untile 3 months	Yes
Secondary	Urodynamics parameters improvement		three months later	Yes